CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment

Area of Science:

• Pharmacogenomics
• Pain Management
• Opioid Metabolism

Background:

• Cytochrome P450 2D6 (CYP2D6) metabolizes key analgesics like hydrocodone, codeine, tramadol, and oxycodone.
• Reduced CYP2D6 activity can impair the effectiveness of these opioids, potentially leading to inadequate pain control.

Purpose of the Study:

• To investigate the association between impaired CYP2D6 activity (due to genotype or inhibitors) and the analgesic efficacy of CYP2D6-metabolized opioids.
• To evaluate the impact of CYP2D6 phenotype on pain-related emergency department (ED) visits.

Main Methods:

• A retrospective cohort study utilized electronic health records and genetic data from the All of Us Research Program.
• Adults prescribed CYP2D6-metabolized opioids for over 7 days were analyzed based on their CYP2D6 phenotype (genotype or inhibitor-mediated).
• The primary outcome was pain-related ED visits within 60 days of opioid initiation, analyzed using inverse probability treatment weighting.

Main Results:

• Reduced CYP2D6 activity was associated with a higher percentage of pain-related ED visits (2.1% vs 1.8%) compared to normal/high activity.
• No significant difference in ED visits was observed for genotypic poor/intermediate metabolizers versus normal/ultrarapid metabolizers across all four drugs.
• CYP2D6 inhibitors increased ED visits in genotypic normal metabolizers, and drug interactions were significant for all four opioids studied.

Conclusions:

• Impaired CYP2D6 activity is associated with an increased risk of emergency department visits in patients treated with CYP2D6-metabolized opioids.
• Integrating CYP2D6 genotype and drug interaction data into clinical practice may optimize opioid prescribing for better pain management and reduced healthcare utilization.